Observational studyViruses2024

Efficacy of Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against Infection from SARS-CoV-2 and Severe COVID-19 among Heavily Immunocompromised Patients: A Single-Center, Prospective, Real-World Study.

Dimitrios Basoulis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.